IMO I would prefer a missed milestone than for the company to submit an incomplete IND Application to the FDA.There was some company commentary toward the end of calendar '22 that it would be submitted in Q.1, 2023.
https://stocknessmonster.com/announcements/ihl.asx-3A607321/ (even though the published milestones mention by the end of Q2 - June)
BUT; The company addressed this technical Q1 miss in the Quarterly Activities on 27th April.
https://stocknessmonster.com/announcements/ihl.asx-3A617110/Now I agree with some of this morning's commentary that some activities can be "out of the control" of management.
Would the BOD be popular with investors if they submitted the IND application with an incomplete "Chemistry and Manufacturing Controls Module" which I guess is coming from Procaps? For the sake of keeping some investors happy by meeting a milestone?
I have posted previously on how important it is for the company to get this IND submitted correctly.
Good luck to all holders, looking forward to the IND news/update soonish.....imminently......anytime now.....